C0879464||FOLFIRINOX
C3665472||Chemotherapy
C0040808||Regimens
C0750952||Biliary Tract Cancers
C0035363||Retrospective Study
C0035363||retrospective study
C0683525||treatment options
C0206698||biliary tract carcinoma
C0206698||biliary tract carcinoma
C1171558||platinum
C0045093||gemcitabine
C0045093||CG
C1171558||platinum
C0016360||fluorouracil
C0016360||CF
C0879464||5-Fluorouracil-oxaliplatin-irinotecan
C0879464||FOLFIRINOX
C3665472||chemotherapy
C0206698||biliary tract carcinoma
C1514821||registered
C0587443||Department of Oncology
C0041740||Gaziantep University
C0936012||analyzed
C0920467||disease control
C1708063||first
C1710038||second-line
C3665472||chemotherapy
C0237913||Log-rank test
C0033489||hazard regression model
C0220825||evaluate
C0035648||risk factors
C0332154||received
C0045093||CG
C0016360||CF
C0879464||FOLFIRINOX
C0040808||regimen
C1708063||first-line
C3665472||chemotherapy
C0045093||CG
C1257890||group
C0016360||CF
C1257890||group
C0879464||FOLFIRINOX
C1257890||group
C0045093||CG
C0016360||CF
C0879464||FOLFIRINOX
C1257890||groups
C1710038||Second-line
C0596581||fluoropyrimidine
C3665472||chemotherapy
C1257890||group
C0045093||gemcitabine
C3665472||chemotherapy
C1257890||group
C1710038||Second-line
C0879464||FOLFIRINOX
C0596581||fuoropyrimidine
C3665472||chemotherapies
C0008972||study
C0220825||evaluating
C0879464||FOLFIRINOX
C0040808||regimen
C0206698||biliary tract carcinoma
C0338265||Cisplatin-gemcitabine
C0087111||therapy
C0206698||BCT
C0879464||FOLFIRINOX
C1710038||second-line treatment
C0206698||biliary tract carcinoma
C3665472||chemotherapy